Context Therapeutics (FRA:6K9) Total Stockholders Equity : €7.77 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Total Stockholders Equity?

Context Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €7.77 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Context Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was €0.49. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Context Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.

Context Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Context Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics Total Stockholders Equity Chart

Context Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

-21.57

-13.91

42.72

32.81

10.89

Context Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial													26.84	22.16	17.23	10.89	7.77

Context Therapeutics (FRA:6K9) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Context Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(7.768	-	0)	/	15.9661
	=	0.49

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Context Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	7.768
	=	0.00

Context Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Context Therapeutics (FRA:6K9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (FRA:6K9) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CNTX:USA 6K9:Germany

Address

2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103

Website

https://www.contexttherapeutics.com

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Context Therapeutics (FRA:6K9) Headlines

No Headlines